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Summary
This report (hereafter referred to as STD QCS) provides CDC recommendations to U.S. health care providers regarding 
quality clinical services for sexually transmitted diseases (STDs) for primary care and STD specialty care settings. These 
recommendations complement CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2015 (hereafter referred to as 
the STD Guidelines), a comprehensive, evidence-based reference for prevention, diagnosis, and treatment of STDs. STD 
QCS differs from the STD Guidelines by specifying operational determinants of quality services in different types of clinical 
settings, describing on-site treatment and partner services, and indicating when STD-related conditions should be managed 
through consultation with or referral to a specialist. These recommendations might also help in the development of clinic-
level policies (e.g., standing orders, express visits, specimen panels, and reflex testing) that can facilitate implementation of 
the STD Guidelines. CDC organized the recommendations for STD QCS into eight sections: 1) sexual history and physical 
examination, 2) prevention, 3) screening, 4) partner services, 5) evaluation of STD-related conditions, 6) laboratory, 
7) treatment, and 8) referral to a specialist for complex STD or STD-related conditions.
CDC developed the recommendations by synthesizing relevant, evidence-based guidelines and recommendations issued 
by other experts; reviewing current practice in the United States; soliciting Delphi ratings by subject matter experts on 
STD care in primary care and STD specialty care settings; discussing the scientific evidence supporting the proposed 
recommendations at a consultation meeting of experts and institutional stakeholders held November 20, 2015, in Atlanta, 
Georgia; conducting peer reviews of draft recommendations and supporting evidence; and discussing draft recommendations 
and supporting evidence during meetings of the CDC/Health Resources and Services Administration Advisory Committee 
on HIV, Viral Hepatitis, and STD Prevention and Treatment STD Work Group. These recommendations are intended to 
help health care providers in primary care or STD specialty care settings offer STD services at their clinical settings and to 
help the persons seeking care live safer, healthier lives by preventing and treating STDs and related complications.
Corresponding author: Roxanne Barrow, MD, National Center for 
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. 
Telephone: 404-639-8503; E-mail: rbarrow@cdc.gov.
Introduction
Background
Approximately 20 million new cases of sexually transmitted 
diseases (STDs) occur every year in the United States, with 
approximately half occurring among persons aged 15–24 years 
(1). In recent years, STDs rates have increased (2). STDs account 
for $16.9 billion annually in health care costs (3). STDs can lead 
to severe reproductive health complications, such as infertility, 
ectopic pregnancy, and congenital infection. In addition, STDs 
can increase a person’s risk for acquiring and transmitting human 
immunodeficiency virus (HIV) infection (4,5).
STDs increasingly are being diagnosed in various health care 
settings. Most reported STD cases are from providers in non-STD 
clinics, such as private physician offices and community health 
centers (2). Historically, STDs were diagnosed in public health 
clinics for reasons of anonymity, confidentiality, and specialized 
care. A principle of STD care is timely management of infections, 
evidenced by the Brussels Agreement of 1924, an international 
treaty that sought to establish STD care in ports for merchant 
marines (6). In the United States, clinics dedicated to caring for 
patients with STDs, such as the first STD clinic in Baltimore, 
Maryland, which opened in 1922, offered confidential care 
to counteract the stigma of syphilis (7). These types of clinics 
increased in number during the 1930s and 1940s, and clinics 
have remained a large component of public health services (8). 
The framework for these STD clinics included timely diagnosis, 
testing with on-site treatment, and partner services.
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During the 1980s and 1990s, most specialized STD care 
was provided in STD clinics and HIV programs (9). For 
patients, STD clinics were unique because they provided 
confidential, walk-in, low-cost specialty care (9) and offered 
the expertise necessary to manage STDs (10). However, because 
of funding issues, public health services and the number of 
STD clinics were reduced substantially during 2008–2012. 
Approximately half of local health departments reported 
reduction or elimination of at least one program, such as 
clinical health services or communicable disease screening and 
treatment, because of funding (11) and at least 10% of STD 
clinics closed (12).
Over time and with decreased availability of STD clinics, 
patients have sought care for STDs at primary care clinics, 
emergency departments, and family planning clinics (13). 
Primary care providers are an important component of sexual 
health care because many patients with STDs are asymptomatic 
and their infections might be identified while receiving services 
in the primary care setting. Certain studies have found that 
primary care clinics might diagnose up to half of reported 
STDs (13). In 2018, 71%–80% of STD cases were reported 
from non-STD clinics (5). One study that examined patients’ 
choice of providers for STD care found that, with expanded 
health care insurance coverage, patient visits to primary care 
providers increased more than 100% and STD clinic visits 
decreased 20%. This increase in primary care visits was largely 
attributable to a rise in the percentage of women seen for 
STD care (14). Despite these shifts in settings for STD service 
provision, publicly funded STD clinics continue to serve as 
a safety net for patients without insurance coverage or other 
marginalized groups of patients seeking care (15).
Rationale
With increasing rates of most STDs in recent years (2), 
all providers have a role in the assessment of STD risk and 
management of infections. STD clinics will continue to be 
locations of expert care and are increasingly recognized as 
venues to provide HIV preexposure prophylaxis (PrEP) to 
prevent incident HIV infections (16). Providers in primary 
care offices, family planning clinics, and community-based 
clinics will continue to diagnose STDs among asymptomatic 
patients who are especially at risk for STDs. Recommendations 
for operationalizing STD care in health care settings are needed 
because provision of STD services varies. This report (hereafter 
referred to as STD QCS) describes what constitutes quality STD 
clinical services in primary care and STD specialty care settings.
In this report, provision of STD care is described as basic or 
specialized. Basic STD care usually is provided in primary care 
settings where patients are seen for various health conditions. 
Typically, specialized STD care is delivered in STD specialty 
care settings that focus on providing timely, comprehensive, 
confidential, and culturally sensitive STD care. Patients with 
STD-related conditions beyond the scope of both primary care 
and STD specialty care settings, such as those needing advanced 
diagnostics (e.g., lumbar punctures or ocular evaluations) or 
inpatient care, should be managed through consultation with 
or referral to a specialist.
CDC’s Sexually Transmitted Diseases Treatment Guidelines, 
2015 (hereafter referred to as the STD Guidelines) provides 
clinical guidance to physicians and other health care providers 
on the prevention, diagnosis, and treatment of STDs in the 
United States (17). The recommendations in STD QCS are 
intended to complement the STD Guidelines; as such, the STD 
Guidelines has not been modified. Rather, this report provides 
guidance on clinical operations and the types of services that 
should be available for STD care. STD QCS describes optimal 
services for the provision of quality STD-related clinical care 
by setting, including services that should be available at the 
time of the patient visit. Availability of same-day, on-site tests 
can reduce diagnostic delays and decrease excessive and costly 
presumptive treatment (18). On-site medications for STDs 
can minimize the duration of infectiousness and reduce STD 
transmission, decrease the cost of staff needed to follow up on 
positive tests and verify treatment, and lessen complications 
in the interval between testing and return visits for therapy 
(19,20). In settings where patient return rates are inconsistent, 
same-day services might result in more cases being diagnosed 
and more patients receiving timely treatment (21). Same-day 
treatment for patients and their sex partners is also critical for 
STD prevention and control because it can reduce transmission 
of STDs in the community.
In the Institute of Medicine* report Crossing the Quality 
Chasm: A New Health System for the 21st Century, the 
framework for health care quality was outlined using the 
following six domains: 1) safety, 2) effectiveness, 3) patient 
centeredness, 4) timeliness, 5) efficiency, and 6) equity (22). 
These domains are essential for the provision of quality STD 
clinical care services:
1. Safety: Patient safety includes the physical health care 
environment; seamless clinic processes; knowledge 
of the patients’ care plan; confidential services, 
especially confidential partner services; and an 
informed patient (22,23).
2. Effectiveness: Effective care includes providing services 
that are consistent with recognized medical and 
laboratory guidelines.
* The name of the Institute of Medicine was changed to the National Academy 
of Medicine, effective July 1, 2015 (http://www.nationalacademies.org/hmd/
Global/News%20Announcements/IOM-to-become-NAM-Press-Release.aspx).
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3. Patient centeredness: A patient-centered approach ensures
• patient confidentiality,
• attention to issues that disproportionally affect 
vulnerable populations,
• guaranteeing a friendly and welcoming environment 
through cultural sensitivity,
• a seamless referral process between health care providers, 
and
• delivery of information and education relevant to a 
patient’s diagnosis, treatment, prognosis, and prevention 
measures.
4. Timeliness: Key factors in ensuring that services are 
provided in a timely manner include availability, 
accessibility, acceptability, and visibility of services 
(e.g., facility location, hours of operation, waiting time 
until appointment, waiting time in the clinic, staffing 
levels, and facility space); availability and selection 
of laboratory technologies and turnaround times for 
laboratory procedures; availability, accessibility, and cost 
of treatments; and availability of partner management 
and other prevention services, such as condoms and 
behavioral counseling (18,23). Timely and appropriate 
STD management can be influenced by several factors, 
including
• patient health care–seeking behaviors,
• diagnostic capabilities,
• treatment capabilities, and
• prevention activities.
5. Efficiency: An efficient health care system optimizes 
its resources by improving safety, effectiveness, patient 
centeredness, and timeliness.
6. Equity: Equity in health care ensures universal access to 
quality care.
Scope and Audience
The recommendations in STD QCS apply to private and 
public providers of STD clinical services, including those in 
primary care settings (e.g., internal medicine, family medicine, 
or obstetrics-gynecology private offices; school-based health or 
community health centers; correctional health care settings; 
or HIV-care clinics) as well as those in sites dedicated to STD 
service delivery (e.g., STD or sexual health clinics). The focus 
is on structural-level policy recommendations about which 
STD-related clinical services should be available to facilitate 
implementation of the STD Guidelines.
In addition to these providers, STD QCS can also be used 
by others, such as
• medical directors to develop protocols that outline clinic 
procedures for delivering STD care,
• public health officials to establish partnerships with local 
care providers to reduce STD clinical service gaps,
• community organizations to stay informed about 
expected STD services for clients,
• health care administrators to measure or monitor health 
care facilities’ adherence to national recommendations,
• health care professionals and patients to advocate for 
quality services, and
• health care organizations to develop quality measures 
for STD services.
STD QCS recommendations address the following questions:
• What STD-related clinical services should be available 
to persons who have or are at risk for STDs, including 
asymptomatic persons, in primary care settings?
• What STD-related clinical services should be available 
to persons who have or are at risk for STDs in STD 
specialty care settings?
• Which STD-related conditions should be managed 
through consultation with or referral to a specialist?
These recommendations allow health care providers to 
build, maintain, or enhance the delivery of STD services in 
their primary care and STD specialty care settings. STD QCS 
is not intended to develop new guidance for when or how 
to provide the services or to mandate or regulate services. 
Health care settings might not provide every service outlined 
for quality STD care; however, the recommendations can 
provide the opportunity to assess which services are available 
in a facility and determine whether additional services can or 
should be made available or whether mechanisms for referral 
can or should be developed.
Methods
Overview
CDC developed these recommendations after consultation 
with a wide range of experts and stakeholders. CDC took into 
account existing national guidelines and recommendations, 
current practice in the United States, Delphi ratings by subject 
matter experts (SMEs) on STD care in primary care and STD 
specialty care settings followed by discussion at a consultation 
meeting, input of external private providers, and feedback 
from the CDC/Health Resources and Services Administration 
(HRSA) Advisory Committee on HIV, Viral Hepatitis, and 
STD Prevention and Treatment (CHAC).
In January 2015, CDC formed a steering committee 
that defined the scope of the proposed recommendations 
and provided feedback to CDC on the development 
process. SMEs on STD care in primary care and STD 
specialty care settings met via conference calls during 
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June–September 2015 to provide individual feedback to CDC 
on the proposed recommendations. CDC developed draft 
recommendations that were discussed at a consultation meeting 
held November 20, 2015, in Atlanta, Georgia. The meeting 
included members of the steering committee, SMEs, federal 
agencies (i.e., CDC, Office of Population Health, and HRSA), 
and other stakeholders. Participants at the consultation meeting 
gave individual feedback on these draft recommendations. 
CDC sought additional input on the draft recommendations 
from private providers identified by stakeholders representing 
professional organizations (i.e., American Academy of Family 
Physicians [AAFP], American Academy of Pediatrics [AAP], 
American Congress of Obstetricians and Gynecologists 
[ACOG], and American College of Physicians [ACP]). Four 
private providers from AAFP provided input. Proposed 
revisions from CHAC were presented and approved at the 
October 2017 CHAC meeting in Rockville, Maryland.
All CDC staff, steering committee members, SMEs, 
and consultation meeting participants disclosed potential 
competing interests. CHAC and CHAC STD Work Group 
members also disclosed potential competing interests.
Literature Review
Recommended STD-related clinical services were identified 
by reviewing relevant evidence-based guidelines and 
recommendations, including recommendations from the STD 
Guidelines, the Advisory Committee on Immunization Practices 
(ACIP), AAP, ACOG, the British Association for Sexual Health 
and HIV, the World Health Organization, and the U.S. 
Preventive Services Task Force (Supplementary Appendix 1, 
https://stacks.cdc.gov/view/cdc/82088). A systematic literature 
search also was conducted to identify current practice for STD 
screening in the United States (Supplementary Appendix 2, 
https://stacks.cdc.gov/view/cdc/82088). Medline and PsycInfo 
databases were searched for studies published from January 1, 
1985, through May 26, 2015, and the Sexually Transmitted 
Diseases journal was searched from January 2006 through 
October 2015. Articles were screened using titles, and 414 
abstracts and relevant full-text articles were retrieved. The 
reference lists of included studies were reviewed and the 
SMEs provided additional relevant citations (Supplementary 
Appendix 3, https://stacks.cdc.gov/view/cdc/82088). The 
inclusion criteria were articles describing original studies or 
systematic reviews that were published in English and that 
included U.S. populations or settings. Commentaries, letters, 
and editorials were excluded.
Delphi Process
Using a modified Delphi process (a method that solicits 
the opinions of experts through a series of questionnaires), 
participating SMEs gave input on what clinical services 
should be available as basic and specialized STD care services 
(24). An online Delphi rating form, developed by CDC 
using SurveyMonkey, included definitions or indications for 
the clinical services. Discussions of the Delphi ratings were 
conducted (two rounds by the SMEs on STD care in primary 
care settings and three rounds by the SMEs on STD care in 
STD specialty care settings) with structured conference calls led 
by a moderator to obtain comments. The Delphi forms were 
modified on the basis of discussions during the conference calls. 
Aggregate results and comments were reviewed and discussed 
during the conference calls. Nine members of the primary 
care setting panel and nine members of the STD specialty 
care setting panel completed the ratings. The most important 
criteria for rating the clinical services was the association with 
quality of STD care and the feasibility of having a service 
available. SME panel members rated each clinical service on the 
basis of their clinical experience. Each service was rated using 
a scale from one to nine, where one indicated disagreement 
with the statement and nine indicated agreement. Median and 
dispersion of the ratings were analyzed to prioritize the clinical 
services, which were classified as appropriate (median rating 
of 7–9 without disagreement), inappropriate (median rating 
of 1–3 without disagreement), or uncertain (median rating 
of 4–6, or any median with disagreement). Disagreement 
was defined as at least three of the nine panelists rating a 
service outside the three-point region containing the median. 
A summary of the rating results is available (Supplementary 
Appendix 4, https://stacks.cdc.gov/view/cdc/82088).
Federal Advisory Committee Review and 
Findings
CHAC is a federal advisory committee that advises the 
U.S. Department of Health and Human Services secretary, 
CDC director, and HRSA administrator about objectives, 
strategies, policies, and priorities for HIV, viral hepatitis, and 
STD prevention and treatment efforts. At the May 2017 
CHAC meeting, the committee approved establishment of 
the CHAC STD Work Group to review and provide feedback 
on the CDC draft recommendations. The CHAC STD Work 
Group consisted of 17 SMEs from the public and private 
sectors. The work group met four times by telephone during 
August–September 2017 to review and discuss proposed 
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revisions from individual members. The summary report was 
presented and approved at the October 2017 CHAC meeting. 
CHAC submitted a letter to the CDC director and the HRSA 
administrator outlining their findings.
Recommendation Format
Recommendations are presented as described in the 
Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE) (25). Strong recommendations are 
worded as “should” and weak recommendations are worded 
as “could.” A strong recommendation implies that all or 
almost all informed providers would choose the recommended 
course of action. A weak recommendation indicates that most 
informed providers would choose the recommended course 
of action but some would not. Delphi ratings were used to 
guide the development of recommendations, and clinical 
services reviewed were classified as appropriate, uncertain, or 
inappropriate and were worded as “should,” “could,” or “would 
not be expected,” respectively.
Current practice, discussion at the consultation meeting, 
and CHAC findings also were considered in formulating the 
strength of the recommendations. The specific guidance for 
prevention strategies, screening, diagnosis, and treatment are 
discussed briefly. More comprehensive information is available 
in the STD Guidelines and other references therein.
Current Practice on Selected Clinical 
Services in the United States
STDs can be prevented using various strategies, including 
male latex condoms, behavioral counseling, preexposure 
vaccination, and presumptive treatment after exposure. Timely 
and appropriate treatment of persons with STDs is critical 
for reducing transmission and preventing complications. 
Prevention and timely treatment of STDs depend on several 
factors, including taking a sexual history, assessing risk for STDs, 
performing screening and diagnostic testing, providing on-site 
medications, and notifying and managing sex partners (18).
Obtaining a sexual history and assessing risk for STDs 
include the five Ps (i.e., partners, practices, protection, past 
STDs, and prevention of pregnancy) (17). Most primary 
care providers obtain a sexual history if it is relevant to the 
chief complaint but less frequently at an initial or routine 
annual visit and seldom at acute care, non-STD–related 
visits (26–32). Adolescent medicine clinicians, pediatricians, 
and obstetricians-gynecologists are more likely to regularly 
take a sexual history than family medicine clinicians, general 
practitioners, and internists (26,28,29,33). Primary care 
providers most commonly inquire about sexual activity and 
history of STDs but less often ask about the number of sex 
partners, gender of sex partners, and specific sexual practices 
(oral, vaginal, or anal sex) (27,29,34,35). Several studies have 
determined that STD clinics obtain more complete sexual 
histories than primary care clinics (36,37).
Screening and diagnostic testing are important to detect 
asymptomatic or confirm suspected infections. Previous studies 
have documented that one third to one half of primary care 
clinicians routinely screen men or women for STDs (chlamydia, 
gonorrhea, syphilis, or HIV) (26,33,38,39). Obstetricians-
gynecologists screen nonpregnant women more often than other 
primary care physicians (39–41). Community health centers 
often provide routine HIV testing for pregnant women but less 
frequently offer routine HIV testing for men and nonpregnant 
women (42,43). Some emergency departments perform routine 
HIV testing, although the practice is not widespread (44). For 
correctional settings, routine testing varies by type of facility. 
State and federal prison systems commonly perform routine 
syphilis testing at intake but less often offer routine testing 
for HIV, gonorrhea, or chlamydia (45). Some city and county 
prisons conduct routine testing for syphilis but rarely offer 
routine testing for HIV, gonorrhea, or chlamydia (45). Jails and 
juvenile detention centers infrequently offer routine testing for 
STDs and rarely perform routine HIV testing (46,47).
In primary care clinics, Gram stain testing for gonorrhea 
usually is not performed on site because of difficulty obtaining 
Clinical Laboratory Improvement Amendments (CLIA) 
certification (48). Among 15 publicly funded STD clinics 
participating in the STD Surveillance Network, testing for 
Trichomonas vaginalis rarely involved culture, rapid antigen 
testing, or nucleic acid amplification test (NAAT); testing was 
almost exclusively performed using wet mount microscopy 
(49). A national survey of public health laboratories reported 
that only one fourth performed direct detection for syphilis. 
However, most laboratories conducted serological testing 
for syphilis (50). A survey of laboratories in the District 
of Columbia that reported gonorrhea results to the health 
department demonstrated that among laboratories that 
conducted gonorrhea cultures, only one third performed 
antibiotic susceptibility testing (51). A study of clinical 
laboratories in California reported that gonorrhea culture 
testing has substantially decreased and gonorrhea and 
chlamydia tests performed using NAAT have increased over 
time (52). For detection of herpes simplex virus (HSV), direct 
antigen and culture testing on lesions have decreased over time 
and serologic testing has increased (52).
If an infected patient receives timely treatment at an initial 
visit, further transmission can be interrupted. In one study, 
uninsured young adults were three to four times more likely to 
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not fill a prescription (53). A study of primary and secondary 
syphilis cases reported to the Arizona STD Control Program 
indicated that treatment at the initial visit occurred more 
frequently for STD clinic patients compared with non-STD 
clinic patients (57% versus 8%) (54,55). A study of gonorrhea 
cases reported to the Philadelphia Department of Public 
Health indicated that among the 3,279 cases with documented 
treatment, 44% of the patients received same-day treatment. 
The median time to treatment for patients not treated the 
same day was 8 days (56). Among 1,241 patients with positive 
gonorrhea or chlamydia screening cultures who did not receive 
empiric treatment at their initial visit at an STD clinic in 
Alabama, 251 (20%) did not return to the clinic for treatment 
within 30 days of screening (57). Among 165 female patients 
with positive chlamydia tests who did not receive empiric 
treatment at their initial visit at a university medical center in 
Alabama, 55 (33%) emergency department or walk-in clinic 
patients and 14 (8%) obstetrics-gynecology patients had no 
treatment documented (58). A study of insured patients in 
50 states indicated that 10% of new prescriptions for STD 
antimicrobials were not filled (59).
Notifying and treating sex partners interrupts transmission, 
prevents reinfection, and might prevent complications from 
unrecognized infections. Studies demonstrate that most 
primary care clinicians instruct patients with STDs to notify 
their sex partners for evaluation and treatment (39,60–63). 
Certain studies have found that approximately 50% of primary 
care clinicians reported ever having used expedited partner 
therapy (EPT) for chlamydia or gonorrhea but a substantially 
lower proportion (6%–27%) reported always or usually 
using this practice (61,62,64,65). Obstetricians-gynecologists 
and family medicine physicians reported using EPT more 
often than internal medicine physicians (63,64). A survey of 
community health centers in Indiana reported that 61% told 
patients with gonorrhea or chlamydia to refer their partner 
for testing and treatment and 18% always gave medication 
to patients to distribute to their partners (66). A survey of 
Federally Qualified Health Centers in New York City reported 
that 80% provided EPT for chlamydia, of which 47% were 
by prescription only, 27% by both prescription and dispensed 
medication, and 6% by dispensed medication only (67). A 
survey of family planning clinics in California found that 19% 
of partners received patient-delivered partner therapy (PDPT) 
and 55% received a patient referral. However, report of the 
partner receiving the treatment was higher for PDPT (80%) 
than for patient referral (44%) (68,69).
Recommendations
STD QCS recommendations are outlined in the following 
eight sections: 1) sexual history and physical examination, 
2) prevention, 3) screening, 4) partner services, 5) evaluation of 
STD-related conditions, 6) laboratory, 7) treatment, and 8) referral 
to a specialist for complex STD or STD-related conditions. 
Boxes 1–7 include the recommendations for basic STD care and 
specialized STD care. Citations of official guidelines and studies 
that support these recommendations accompany each section 
of recommendations. Box 8 includes a list of complex STD or 
STD-related conditions that primary care and STD specialty care 
settings should refer to a specialist.
Sexual History and Physical Examination
A sexual history and risk assessment are foundational to 
providing quality STD care services (17,70,71). A complete 
sexual history includes inquiring about the five Ps (i.e., partners, 
practices, protection, past history of STDs, and prevention of 
pregnancy) (17). A Guide to Taking a Sexual History is available 
(https://www.cdc.gov/std/treatment/sexualhistory.pdf ). The 
sexual history and risk assessment should be available as part of 
an initial comprehensive or annual visit; a visit for reproductive, 
genital, or urologic issues; or a visit for STD-related symptoms, 
STD-related concerns, or concerns about preventing or 
achieving pregnancy. The sexual history and risk assessment 
might be provided during an HIV, PrEP, or acute care visit.
A physical examination for STDs includes inspection 
of the skin, pharynx, lymph nodes, anogenital area, and 
neurologic system. The examination can provide useful 
information among males and females with STD-related 
symptoms (17,70–73). A physical examination allows health 
care providers the opportunity to identify the presence of any 
signs of STDs of which a patient might or might not be aware.
An anogenital examination for females includes a pelvic 
examination with three elements: 1) inspection of the 
external genitalia, urethral meatus, vaginal introitus, and 
perianal region; 2) speculum examination of the vagina and 
cervix; and 3) bimanual examination of the uterus, cervix, 
and adnexa (72). A colposcopy might be a useful procedure 
to examine the cervix, vagina, and vulva more closely for 
signs of disease and is recommended for those patients with 
abnormal Papanicolaou smear tests (Pap smears) according to 
the American Society for Colposcopy and Cervical Pathology 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801360). 
An anogenital examination for males includes an external 
genital examination and inspection of the penis, scrotum, 
scrotal contents, and perianal region (74). An anoscopy can 
assist with the visualization of the anal canal among patients 
with rectal symptoms or history of receptive anal intercourse.
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Sexual history and physical examination recommendations are 
summarized (Box 1). Additional information on sexual history and 
physical examination recommendations is available (Supplementary 
Appendix 1, https://stacks.cdc.gov/view/cdc/82088).
Prevention
Services for preventing STDs and related conditions, 
including HIV, consist of eight strategies. These are 1) condom 
provision (17,70,75); 2) hepatitis A vaccination (17,76); 
3) hepatitis B vaccination (17,77); 4) human papillomavirus 
(HPV) vaccination (78,79); 5) emergency contraceptive 
pills (17,80,81); 6) STD/HIV prevention counseling (brief, 
moderate intensity, or high intensity) (17,82–84); 7) PrEP 
for HIV prevention risk assessment, education, counseling, 
provision, and linking or referral, or both (85); and 
8) nonoccupational postexposure prophylaxis (nPEP) of HIV 
risk assessment, education, counseling, provision, and linking 
or referral, or both, to HIV care (86).
STD/HIV prevention counseling, including behavioral 
counseling methods, can be used by health care providers to 
effect patient changes to reduce the patient’s risk for STD 
acquisition and transmission. The methods vary in scope and 
time. Brief prevention counseling is conducted in a single 
session using strategies, such as motivational interviewing and 
building rapport, and includes patient circumstances and needs 
in the counseling plan. Moderate-intensity and high-intensity 
behavioral counseling is contact time of 30–120 minutes 
and ≥2 hours, respectively (82). Contraceptive counseling 
enables clients to make and follow through on decisions about 
their contraceptive use. Education is an integral component 
of the contraceptive counseling process and helps clients 
make informed decisions and obtain information needed to 
use contraceptive methods correctly. Guidance for clinical 
providers on contraceptive services are outlined in Providing 
Quality Family Planning Services: Recommendations of CDC 
and the U.S. Office of Population Affairs (87). Linkage to care 
and helping patients start HIV medical care shortly after 
diagnosis can enhance prompt delivery of important services 
and support efforts to eliminate HIV infection (83). Linkage 
to HIV care, family planning, and behavioral health services 
can increase the proportion of those living with HIV who 
are virally suppressed, reduce unintended pregnancies, and 
maximize long-term behavioral health. Guidance for clinical 
providers on linkage to and retention in HIV medical care is 
outlined in the Recommendations for HIV Prevention with Adults 
and Adolescents with HIV in the United States, 2014 Summary 
for Clinical Providers (88).
Prevention recommendations are outlined (Box 2). 
Additional information on prevention recommendations is 
available (Supplementary Appendix 1, https://stacks.cdc.gov/
view/cdc/82088).
BOX 1. Recommendations for obtaining a sexual history and conducting a physical examination as part of sexually transmitted diseases care 
in primary care and sexually transmitted diseases specialty care settings*
STD care in primary care settings
• A sexual history and risk assessment should be available as 
part of basic STD care services at the following patient visits:
 ű Initial comprehensive or annual visit
 ű Each visit concerning reproductive, genital, or 
urologic issues
• A physical examination should be available as a basic 
STD care service for male and female patients with 
STD-related symptoms, STD-related concerns, or those 
at high behavioral risk for incident STDs.
• A pelvic examination should be available as a basic STD 
care service.
• A sexual history and risk assessment could be available 
as basic STD care services at each visit unrelated to 
reproductive, genital, or urologic concerns.
• Anoscopy could be available as a basic STD care service.
STD care in STD specialty care settings
• A sexual history and risk assessment should be part of 
specialized STD care services at every visit for patients 
with STD-related symptoms, STD-related concerns, or 
concerns about preventing or achieving pregnancy.
• A physical examination should be available as a 
specialized STD care service for male and female 
patients with STD-related symptoms, STD-related 
concerns, or high behavioral risk for incident STDs.
• A pelvic examination should be available as a specialized 
STD care service.
• Colposcopy should be available as a specialized STD care 
service for female patients with abnormal Pap smears.
• Anoscopy should be available as a specialized STD care service.
• A high-resolution anoscopy could be available as a 
specialized STD care service for patients with abnormal 
anal Pap smears.
Abbreviations: Pap = Papanicolaou; STD = sexually transmitted disease.
* Primary care setting is defined as a place where patients are evaluated for various health conditions. An STD specialty care setting is defined as a place where the 
focus is on providing patients with timely, comprehensive, confidential, and culturally sensitive STD care. STD care delivered in STD specialty care settings 
includes all care delivered in primary care settings.
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BOX 2. Prevention recommendations for sexually transmitted diseases care in primary care and sexually transmitted diseases specialty care settings*
STD care in primary care settings
• The following prevention services should be available as 
basic STD care services:
 ű On-site hepatitis B vaccination or referral
 ű On-site HPV vaccination or referral
 ű Brief single STD/HIV prevention counseling session 
(up to 30 minutes)†
 ű PrEP for HIV prevention and nPEP of HIV risk 
assessment, education, and referral or link to HIV care†
 ű Emergency contraceptive pills§
 ű Brief contraceptive counseling or referral
 ű Referral or link to HIV care, family planning services, 
and behavioral health services, if indicated
• The following prevention services could be available as 
basic STD care services:
 ű On-site condom provision¶
 ű On-site hepatitis A vaccination
 ű Provision of PrEP for HIV prevention**
 ű Provision of nPEP of HIV††
 ű Moderate-intensity STD behavioral counseling  
(≥30 minutes)†
STD care in STD specialty care settings
• The following prevention services should be available as 
specialized STD care services:
 ű On-site condom provision
 ű On-site hepatitis A vaccination
 ű On-site hepatitis B vaccination
 ű On-site HPV vaccination
 ű Brief single STD/HIV prevention counseling session 
(up to 30 minutes)†
 ű PrEP for HIV prevention and nPEP of HIV risk 
assessment, education, counseling, and referral or link 
to HIV care†
 ű Provision of PrEP for HIV prevention§§
 ű Provision of nPEP of HIV¶¶
 ű Brief contraceptive counseling or referral
 ű Emergency contraceptive pills§
 ű Referral or link to HIV care, family planning services, 
and behavioral health services, if indicated
• The following prevention services could be available as 
specialized STD care services:
 ű Moderate-intensity STD behavioral counseling  
(≥30 minutes)†
 ű High-intensity STD behavioral counseling (≥2 hours)†
Abbreviations: HIV = human immunodeficiency virus; HPV = human papillomavirus; nPEP = nonoccupational postexposure prophylaxis; PrEP = preexposure 
prophylaxis; STD = sexually transmitted disease.
 * Primary care setting is defined as a place where patients are evaluated for various health conditions. STD specialty care setting is defined as a place where the 
focus is on providing patients with timely, comprehensive, confidential, and culturally sensitive STD care. STD care delivered in STD specialty care settings 
includes all care delivered in primary care settings.
 † Provided by a clinician or other appropriately trained staff.
 § If emergency contraceptive pills are not available on site or by prescription, patients can be advised that levonorgestrel emergency contraceptive pills are available 
over the counter and ulipristal acetate emergency contraceptive pills are only available by prescription. Emergency contraceptive pills should be taken as soon 
as possible within 5 days of unprotected sex.
 ¶ Providers can partner with local organizations, such as the local health department and community-based organizations, to procure condoms. In some states, 
prescriptions can be written for condoms. For certain settings, such as family planning clinics, condoms should be available on site.
 ** PrEP could be available by starter packs or prescription with on-site follow-up care for basic STD care. If PrEP is not provided, navigator-assisted referral for 
PrEP should be provided with first appointment made while the patient is on site.
 †† nPEP starter pack (3–7 days of medication) could be available on site, with either on-site follow-up care or referral for basic STD care. nPEP starter pack or 
complete 28-day course could be available by prescription, with either on-site follow-up care or referral, with first appointment made while the patient is on 
site. Provision of the complete 28-day nPEP medication supply at the initial visit rather than a starter pack of 3–7 days has been reported to increase likelihood 
of adherence, especially when patients find returning for multiple follow-up visits difficult. Routinely providing starter packs or the complete 28-day course 
requires that health care providers stock nPEP drugs in their practice setting or have an established agreement with a pharmacy to stock, package, and urgently 
dispense nPEP drugs with required administration instructions (https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf ).
 §§ PrEP should be available in starter packs or by prescription with on-site follow-up care for specialized STD care. If PrEP is not provided, navigator-assisted 
referral for PrEP should be provided with first appointment made while the patient is on site.
 ¶¶ nPEP starter pack (3–7 days of medication) should be available on site, with either on-site follow-up care or referral to specialized STD care. nPEP complete 
28-day course should be available by prescription, with either on-site follow-up care or referral, with first appointment made while the patient is on site. 
Provision of the complete 28-day nPEP medication supply at the initial visit rather than a starter pack of 3–7 days has been reported to increase likelihood of 
adherence, especially when patients find returning for multiple follow-up visits difficult.
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Screening
Screening for asymptomatic STDs is important for early 
detection and prevention of STDs. Because many STDs 
are asymptomatic, testing is the only method to diagnose 
these infections. The availability of screening tests are key 
for identifying gonorrhea, chlamydia, syphilis, hepatitis B, 
hepatitis C, HIV, trichomoniasis, and cervical and anal cancer 
(17,84,89–99). Results from these screening tests can be 
used to identify persons at risk for STDs (17). Data are 
insufficient to recommend routine anal cancer screening 
with anal cytology among persons with HIV infection, men 
who have sex with men (MSM) without HIV infection, and 
the general population (17). However, some clinical centers 
perform anal cytology to screen for anal cancer among high-risk 
populations followed by a high-resolution anoscopy for those 
with abnormal cytologic results. Colposcopy is a recommended 
tool for cervical cancer screening.
A table summarizing screening recommendations for 
women, pregnant women, men, MSM, and persons with HIV 
is available (https://www.cdc.gov/std/treatment-guidelines/). 
Recommendations for STD screening are listed (Box 3). 
Additional information on screening recommendations is 
available (Supplementary Appendix 1, https://stacks.cdc.gov/
view/cdc/82088).
Partner Services
Treatment of sex partners prevents reinfection and is essential 
to interrupting transmission of STDs. Partner services consist 
of various strategies with differing levels of time and effort to 
enable persons who are exposed to an STD to be identified, 
tested, and treated. These strategies include 1) guidance 
regarding notification and care of sex partners, 2) interactive 
counseling for partner notification, 3) EPT, and 4) health 
department disease intervention specialist (DIS) elicitation of 
sex partner information to identify those who might be infected 
and to identify patient follow-up needs (17,83,100–106).
Guidance regarding notification and care of sex partners 
is described as providers giving how-to information to their 
patients about the need to notify their sex partner or partners 
of the exposure, the need for sex partners to seek care and 
treatment even if they do not have symptoms, and where a 
partner could go for STD care. This strategy typically does 
not require extensive staff training. Guidance might be verbal 
or written. When notifying patients of an STD diagnosis and 
need to return for treatment, providers can advise patients to 
bring their sex partner with them, at which time the provider 
should treat both persons concurrently (69).
In interactive counseling, the provider and patient both 
actively participate in an individualized plan to notify the 
patient’s sex partner or partners. Interactive counseling 
typically is conducted by staff with specific training or skills 
in communication, interviewing, or counseling. The patient 
provides information about their sex partner or partners 
and develops a plan with the counselor to notify partners. 
Notification might involve the patient, the provider, or 
the health department. Efforts to notify partners can be 
documented and assessed.
BOX 3. Screening recommendations for sexually transmitted diseases care in primary care and sexually transmitted diseases specialty care settings*
STD care in primary care settings
• Screening and assessment for the following STDs 
should be available as basic STD care services:
 ű Gonorrhea
 ű Chlamydia
 ű Syphilis
 ű Hepatitis B
 ű Hepatitis C
 ű HIV
 ű Cervical cancer
• Screening and assessment for the following STD could 
be available as a basic STD care service:
 ű Trichomoniasis
STD care in STD specialty care settings
• Screening and assessment for the following STDs 
should be available as specialized STD care services:
 ű Gonorrhea
 ű Chlamydia
 ű Syphilis
 ű Hepatitis B
 ű Hepatitis C
 ű HIV
 ű Cervical cancer
 ű Trichomoniasis
• Screening and assessment for the following STD could 
be available as a specialized STD care service:
 ű Anal cancer
Abbreviations: HIV = human immunodeficiency virus; STD = sexually transmitted disease.
* Primary care setting is defined as a place where patients are evaluated for various health conditions. STD specialty care setting is defined as a place where the focus 
is on providing patients with timely, comprehensive, confidential, and culturally sensitive STD care. STD care delivered in STD specialty care settings includes all 
care delivered in primary care settings.
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EPT typically is recommended for sex partners of patients who 
have received a diagnosis of chlamydia or gonorrhea, or both, 
and who are unlikely to access timely care. This is a method that 
provides medications or prescriptions to the patient to take to 
a partner without the partner first being examined by a health 
care provider. EPT is legislated or regulated at the state level, and 
what each state allows can vary by STD, age group, and sexual 
orientation. Details about EPT are available (https://www.cdc.
gov/std/ept/default.htm). For these methods, treatment and 
infection status of the partner can be verified and documented 
along with any co-occurring conditions (e.g., HIV infection or 
pregnancy) and health care access.
A DIS is a public health professional with applied expertise in 
client-centered interviews; partner services that include contact 
tracing, directly observed therapy, field specimen collection, and 
field investigation in outbreaks; and navigation of health care 
systems to ensure patient evaluation and treatment, among other 
areas (107). The position does not require a license, although 
persons with medical licenses sometimes serve in DIS positions. 
Relevant program areas include STD, HIV, tuberculosis, other 
communicable diseases, outbreak investigation, and emergency 
preparedness and response. DISs investigate STDs mandated 
by jurisdictional needs. Providers in health care settings are 
encouraged to develop relationships with their local health 
departments so that they can involve DISs in the cases routinely 
investigated on the basis on resources available in the jurisdiction 
and better inform their patients about DIS services.
Partner services recommendations are outlined (Box 4). Additional 
information on these recommendations is available (Supplementary 
Appendix 1, https://stacks.cdc.gov/view/cdc/82088).
Evaluation of STD-Related Conditions
Genital ulcer disease can be caused by syphilis, HSV, 
chancroid, granuloma inguinale, and lymphogranuloma 
venereum (LGV). The more common sexually transmitted 
causes of male urethritis syndrome can include gonorrhea, 
chlamydia, mycoplasma, trichomoniasis, and HSV. Diseases 
characterized by vaginal discharge as a result of vaginitis can 
include bacterial vaginosis, trichomoniasis, and candidiasis. 
The causes of epididymitis, pharyngitis, cervicitis, and pelvic 
inflammatory disease (PID) can include gonorrhea and 
chlamydia. Most genital warts are caused by nononcogenic 
HPV types. However, on occasion, oncogenic types can be 
found in genital warts. Proctitis can be caused by gonorrhea, 
LGV serovars of Chlamydia trachomatis, syphilis, and HSV. 
Ectoparasitic infections typically include pediculosis pubis 
and scabies. Systemic or dermatologic conditions compatible 
with or suggestive of an STD can include disseminated 
gonorrhea, neurosyphilis, ocular syphilis, condylomata lata, 
or palmar plantar syphilitic rash. STD-related conditions 
warrant prompt evaluation of signs and symptoms to make 
an accurate diagnosis and provide timely empiric treatment to 
prevent complications and onward transmission. Patients with 
a clinical presentation suggestive of an STD etiology (genital 
ulcer disease, urethritis, vaginal discharge, PID, epididymitis, 
pharyngitis, genital warts, proctitis, ectoparasitic infections, 
or certain systemic or dermatologic conditions) should be 
evaluated (17,70,71).
Recommendations for the STD-related conditions that should 
be evaluated are summarized (Box 5). Additional information 
BOX 4. Partner services recommendations for sexually transmitted diseases care in primary care and sexually transmitted diseases specialty 
care settings*
STD care in primary care settings
• The following partner services should be available as 
basic STD care services:
 ű Guidance regarding notification and care of 
sex partners
 ű EPT (where legal and where local or state 
jurisdictions do not prohibit by regulation)†
• The following partner services could be available as a 
basic STD care service:
 ű Interactive counseling for partner notification
STD care in STD specialty care settings
• The following partner services should be available as 
specialized STD care services:
 ű Guidance regarding notification and care of 
sex partners
 ű Interactive counseling for partner notification
 ű EPT (where legal and where local or state 
jurisdictions do not prohibit by regulation)†
 ű Health department DIS elicitation of sex partner 
information to identify those who might have been 
exposed and to identify patient follow-up needs§
Abbreviations: DIS = disease intervention specialist; EPT = expedited partner therapy; STD = sexually transmitted disease.
* Primary care setting is defined as a place where patients are evaluated for various health conditions. STD specialty care setting is defined as a place where the focus 
is on providing patients with timely, comprehensive, confidential, and culturally sensitive STD care. STD care delivered in STD specialty care settings includes all 
care delivered in primary care settings.
† Information on legal status of EPT for each state is available at https://www.cdc.gov/std/ept/legal/default.htm.
§ Partner services can be provided on site or by referral.
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BOX 5. Evaluation of sexually transmitted disease–related conditions recommendations in primary care and sexually transmitted diseases 
specialty care settings*
STD care in primary care settings
• Evaluation (history and examination) for the following 
STD-related conditions should be available as basic 
STD care services:
 ű Genital ulcer disease
 ű Male urethritis syndrome
 ű Vaginal discharge
 ű PID
 ű Genital warts
 ű Proctitis†
 ű Ectoparasitic infections
 ű Pharyngitis
 ű Epididymitis
 ű Systemic or dermatologic conditions compatible with 
or suggestive of an STD etiology
STD care in STD specialty care settings
• Evaluation (history and examination) for the following 
STD-related conditions should be available as 
specialized STD care services:
 ű Genital ulcer disease
 ű Male urethritis syndrome
 ű Vaginal discharge
 ű PID
 ű Genital warts
 ű Proctitis†
 ű Ectoparasitic infections
 ű Pharyngitis
 ű Epididymitis
 ű Systemic or dermatologic conditions compatible with 
or suggestive of an STD etiology
Abbreviations: PID = pelvic inflammatory disease; STD = sexually transmitted disease.
* Primary care setting is defined as a place where patients are evaluated for various health conditions. STD specialty care setting is defined as a place where the 
focus is on providing patients with timely, comprehensive, confidential, and culturally sensitive STD care. STD care delivered in STD specialty care settings 
includes all care delivered in primary care settings.
† Evaluation for proctitis might include visual examination of the anus, anorectal examination with a rectal swab, digital anorectal exam, or anoscopy. For specialized 
STD care, high-resolution anoscopy might be included.
on these recommendations is available (Supplementary 
Appendix 1, https://stacks.cdc.gov/view/cdc/82088).
Laboratory
Tests cleared by the U.S. Food and Drug Administration 
(FDA) are available for identifying STDs. Certain tests can 
be performed as point-of-care tests, either on site or through 
a clinical laboratory with rapid turnaround times. Providing 
results during the same clinic visit is ideal. Typically, these 
tests are waived by CLIA or are moderately complex. Use of 
commercially available NAATs for gonorrhea and chlamydia 
is cleared by FDA for genital tract specimens (17,90).
Laboratory tests for identifying STDs are important for 
screening and diagnostic purposes. Screening tests are the 
only method for identifying asymptomatic infections. To 
improve rates of recommended screenings, primary care and 
STD specialty care providers can implement structural-level 
policy interventions in clinical settings, such as standing 
orders for the registration staff, express visits, specimen 
panels, and reflex testing. For patients, a sexual history and 
risk assessment can help determine whether a screening test 
is necessary. For patients with STD-related symptoms, both 
a physical examination and laboratory testing are needed 
along with a sexual history and risk assessment to determine 
the possible cause of symptoms and provide an opportunity 
for the diagnosis of other, unrecognized infections. In STD 
specialty care settings, same-day diagnosis and treatment are 
core functions for both health care and public health outcomes. 
With rapid laboratory results, treatment delays are reduced, 
resulting in fewer complications, less onward transmission 
of STDs, less time spent tracking and verifying treatment 
for those who fail to return after a positive test result, and 
more prudent use of antimicrobials based on less empiric 
treatment. STD specialty care settings should offer same-day 
diagnostic testing and treatment for patients with STD-related 
conditions and for sex partners of patients with a diagnosed 
sexually transmitted infection. Laboratory recommendations 
are outlined (Box 6).
Treatment
In settings where same-day treatment is available for patients 
with STD-related conditions and for sex partners of patients 
with a diagnosed STD, treatment should not be delayed 
while awaiting diagnostic test results. Delays in treatment 
might increase complications and contribute to transmission 
of infection in the community; and same-day treatment has 
numerous public health benefits. In an STD specialty care 
setting, same-day treatment should take place on site with the 
provision of a full course of appropriate medication. The first 
dose should be administered while the patient is in the clinic.
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BOX 6. Laboratory recommendations for sexually transmitted diseases care in primary care and sexually transmitted diseases specialty care settings*
STD care in primary care settings
At the time of the patient visit
• The following general services, equipment, or tests 
should be available as basic STD care services at the 
time of the patient visit:
 ű Thermometer
 ű pH paper
• The following general services, equipment, or tests 
could be available as basic STD services with test results 
available during the patient visit:
 ű Phlebotomy
 ű Test for trichomoniasis†
 ű Test for bacterial vaginosis§
 ű Test for vulvovaginal candidiasis¶
 ű Urine dipstick
 ű Urinalysis with microscopy
 ű Test for pregnancy
 ű Test for HIV
Clinical laboratory
• The following tests should be available through clinical 
laboratory as basic STD care services:
 ű Urogenital NAAT for gonorrhea and chlamydia
 ű Extragenital (pharynx and rectum) NAAT for 
gonorrhea and chlamydia
 ű Quantitative nontreponemal serologic test for syphilis
 ű Treponemal serologic test for syphilis
 ű HSV viral culture or PCR
 ű HSV serology
 ű Fourth-generation antigen/antibody HIV test
 ű Oncogenic HPV NAATs with Pap smear
 ű nPEP and PrEP
 ű Serologic tests for hepatitis A, B, and C
 ű Test for pregnancy
• The following tests could be available through clinical 
laboratory as basic STD care services:
 ű Gram stain, methylene blue, or gentian violet stain 
for urethritis
 ű Gonorrhea culture
 ű Gonorrhea antimicrobial susceptibility testing**
 ű NAAT for trichomoniasis
STD care in STD specialty care settings
At the time of the patient visit
• The following general services, equipment, or tests 
should be available as specialized STD care services at 
the time of the patient visit:
 ű Thermometer
 ű pH paper
 ű Phlebotomy
 ű Test for trichomoniasis†
 ű Test for bacterial vaginosis§
 ű Test for vulvovaginal candidiasis¶
 ű Urine dipstick
 ű Urinalysis with microscopy
 ű Test for pregnancy
 ű Gram stain, methylene blue, or gentian violet stain 
for urethritis
 ű On-site qualitative nontreponemal serologic test 
for syphilis
• The following general services, equipment, or tests 
could be available as specialized STD care services with 
test results available during the patient visit:
 ű Dark-field microscopy for syphilis
 ű Test for HIV
Clinical laboratory
• The following tests should be available through a 
clinical laboratory as specialized STD care services:
 ű Urogenital NAAT for gonorrhea and chlamydia
 ű Extragenital (pharynx and rectum) NAAT for 
gonorrhea and chlamydia
 ű Quantitative nontreponemal serologic test for syphilis
 ű Treponemal serologic test for syphilis
 ű HSV viral culture or PCR
 ű HSV serology
 ű Fourth-generation antigen/antibody HIV test
 ű Oncogenic HPV NAATs with Pap smear
 ű nPEP and PrEP
 ű Serologic tests for hepatitis A, B, and C
 ű Gonorrhea culture
 ű Gonorrhea antimicrobial susceptibility testing**
 ű NAAT for trichomoniasis
Abbreviations: HIV = human immunodeficiency virus; HPV = human papillomavirus; HSV = herpes simplex virus; NAAT = nucleic acid amplification test; 
nPEP = nonoccupational postexposure prophylaxis; Pap = Papanicolaou; PCR = polymerase chain reaction; PrEP = preexposure prophylaxis; STD = sexually 
transmitted disease.
 * Primary care setting is defined as a place where patients are evaluated for various health conditions. STD specialty care setting is defined as a place where the 
focus is on providing patients with timely, comprehensive, confidential, and culturally sensitive STD care. STD care delivered in STD specialty care settings 
includes all care delivered in primary care settings.
 † On-site test for trichomoniasis can include wet mount microscopy and OSOM Trichomonas.
 § On-site test for bacterial vaginosis can include wet mount microscopy, OSOM BVBlue, and Affirm.
 ¶ On-site test for vulvovaginal candidiasis can include wet mount microscopy.
 ** Access needs to be established for transport medium that adequately maintains the viability of Neisseria gonorrhoeae until the specimen reaches a laboratory 
(e.g., transport medium in transport container, transport system, or transport swab). Providers should contact their state or local health department if they 
have concerns about resistant N. gonorrhoeae infection or if assistance is required for culture and antimicrobial susceptibility testing.
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The STD Guidelines includes recommended regimens for 
treating STDs (17). An STD treatment guide app (STD 
Tx Guide), based on the STD Guidelines, is available free 
of charge for Apple and Android devices (https://www.cdc.
gov/std/treatment-guidelines). Wall charts and pocket guides 
that include a summary of the guidelines for recommended 
medications, doses, and duration of therapy are also available 
at the link.
For STD care in primary care settings, the following 
treatments could be available on site: recommended 
medications for chlamydia and gonorrhea, medications used 
as first-line therapies for STD-related conditions (urethritis, 
cervicitis, PID, epididymitis, and proctitis), recommended 
medications for syphilis, emergency contraceptive pills, PrEP, 
nPEP, and provider-applied regimens for genital warts. If 
medications are not available on site, they should be available 
by prescription. Ideally, tracking systems to verify that the 
medications were picked up should be established for STD 
prescriptions. Providers might not receive reimbursement 
for oral medications without an on-site pharmacy. Providers 
can partner with local organizations, such as the local health 
department and community-based organizations, to procure 
oral medications. For syphilis treatment, providers can partner 
with local health departments to procure injectable medication.
For STD care in STD specialty care settings, recommended 
medications for common STDs and related conditions should be 
available on site with the exception of medications for bacterial 
vaginosis, candida vaginitis, urinary tract infections, ectoparasitic 
infections, and patient-applied regimens for genital warts. If 
medications are not available on site, they should be available 
by prescription. Sex partners should be treated as outlined in the 
STD Guidelines. Medications for sex partners of patients with 
gonorrhea, or both, should also be available on site and managed 
in accordance with state EPT laws and regulations. Alternative 
medications for chlamydia, gonorrhea, and syphilis, provider-
applied regimens for genital warts, emergency contraceptive pills, 
and nPEP should be available on site. PrEP could be available 
on site. Specific guidance on provision of nPEP starter packs 
or a 28-day supply at initiation is available (https://stacks.cdc.
gov/view/cdc/38856). Information on linkage to care is available 
(https://stacks.cdc.gov/view/cdc/44065). The treatment 
recommendations are listed (Box 7).
Referral to a Specialist for Complex STD or 
STD-Related Conditions
The STD Guidelines specifies conditions that should be 
managed through referral to a specialist (17). Referrals should 
be made to clinicians who have extensive specialized training 
or experience in diagnosing, treating, and providing follow up 
for complex STD cases. These providers can include adult and 
pediatric infectious disease clinicians, maternal-fetal medicine 
specialists, allergists, ophthalmologists, gastroenterologists, 
colorectal surgeons, urologists, oncologists, and other 
specialists. Services can be provided in different sites within a 
multispecialty practice or hospital system. Recommendations 
on referral to a specialist for complex STD or STD-related 
conditions are described (Box 8).
Future Directions
Research is needed to identify facilitators, barriers, and 
unintended consequences of implementing the recommendations 
for the specified STD or related clinical services in primary 
care and specialized STD care settings. High-priority research 
includes studies to quantify the impact of on-site or point-of-care 
services on patient compliance and health outcomes in various 
provider settings and patient populations.
Conclusion
The recommendations in this report contribute to improved 
STD care by defining the STD or related clinical services 
that should be available in primary care and STD specialty 
care settings. Specialized STD care focuses on the delivery of 
timely, comprehensive, confidential, and culturally sensitive 
STD clinical services. Specialized STD care also preferably 
includes on-site immediate diagnosis (e.g., Gram stain or other 
stains for urethritis or stat nontreponemal serologic tests for 
syphilis) and on-site injectable antimicrobials to treat syphilis 
and gonorrhea. STD care in primary care settings might offer 
some of the same services as specialized STD care settings 
but, at a minimum, should encompass sexual history and risk 
assessment, screening, and treatment services. This guidance 
complements CDC’s STD Guidelines and outlines services 
for providing quality STD clinical services in primary care 
and STD specialty care settings. CDC will update STD QCS 
recommendations as more evidence become available and new 
practice standards are implemented.
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BOX 7. Treatment recommendations for sexually transmitted diseases care in primary care and sexually transmitted diseases specialty care settings*
STD care in primary care settings
On site
• Medications for the following could be available on 
site as basic STD care services:
 ű Gonorrhea†
 ű Chlamydia†
 ű Cervicitis
 ű Nongonococcal urethritis†
 ű Proctitis
 ű PID
 ű Epididymitis
 ű Syphilis§
 ű PrEP
 ű nPEP
 ű Provider-applied regimens for genital warts
 ű Emergency contraceptive pills¶
Prescription
• All recommended medications for the following should 
be available by prescription as basic STD care services:
 ű EPT for gonorrhea and chlamydia**
 ű Herpes
 ű Trichomoniasis
 ű Bacterial vaginosis
 ű Vulvovaginal candidiasis
 ű UTI
 ű PrEP
 ű nPEP
 ű Emergency contraceptive pills¶
 ű Patient-applied regimens for genital warts
 ű Ectoparasitic infections
STD care in STD specialty care settings
On site
• Medications for the following should be available on 
site as specialized STD care services:
 ű Gonorrhea
 ű Chlamydia
 ű Cervicitis
 ű Nongonococcal urethritis
 ű Proctitis
 ű PID
 ű Epididymitis
 ű Syphilis
 ű nPEP
 ű Provider-applied regimens for genital warts
 ű Emergency contraceptive pills¶
 ű EPT for gonorrhea and chlamydia**
 ű Herpes
 ű Trichomoniasis
• Medications for the following could be available on site 
as specialized STD care services:
 ű Bacterial vaginosis
 ű Acute or new diagnosis of HIV care
 ű PrEP
 ű Persistent and recurrent cervicitis and nongonococcal 
urethritis
Prescription
• All recommended medications for the following should be 
available by prescription as specialized STD care services:
 ű Vulvovaginal candidiasis
 ű UTI
 ű PrEP 
 ű Patient-applied regimens for genital warts
 ű Ectoparasitic infections
Abbreviations: EPT = expedited partner therapy; HIV = human immunodeficiency virus; nPEP = nonoccupational postexposure prophylaxis; PID = pelvic 
inflammatory disease; PrEP = preexposure prophylaxis; STD = sexually transmitted disease; UTI = urinary tract infection.
 * Primary care setting is defined as a place where patients are evaluated for various health conditions. STD specialty care setting is defined as a place where the 
focus is on providing patients with timely, comprehensive, confidential and culturally sensitive STD care. STD care delivered in STD specialty care settings 
includes all care delivered in primary care settings.
 † Providers might not receive reimbursement for oral medications without an on-site pharmacy. Providers can partner with local organizations, such as the local 
health department and community-based organizations, to procure oral medications or refer patients to local organizations. 
 § Providers can partner with local health departments to procure injectable benzathine penicillin G or refer patients to local health department and verify treatment.
 ¶ If emergency contraceptive pills are not available on site or by prescription, patients can be advised that levonorgestrel emergency contraceptive pills are available 
over the counter and ulipristal acetate emergency contraceptive pills are only available by prescription. Emergency contraceptive pills should be taken as soon 
as possible within 5 days of unprotected sex.
 ** Information on the legal status of EPT for each state is available at https://www.cdc.gov/std/ept/legal/default.htm.
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BOX 8. Recommendations on referral to specialist for complex sexually transmitted diseases or sexually transmitted disease–related conditions
Complex gonorrhea
• Antimicrobial-resistant gonorrhea
• Cephalosporin or IgE-mediated penicillin allergy
• Suspected cephalosporin treatment failure
• Gonococcal conjunctivitis
• Disseminated gonococcal infection or gonococcal 
endocarditis or meningitis
• Gonococcal ophthalmia in infants
Complex chlamydial infections
• Chlamydial ophthalmia in infants
• Pneumonia in infants
• Persistent or recurrent epididymitis
• Persistent or recurrent cervicitis
• Cephalosporin or IgE-mediated penicillin allergy
• Suspicion of testicular torsion
Complex syphilis
• Primary, secondary, and latent syphilis in infants and 
children
• IgE-mediated penicillin allergy
• Tertiary syphilis
• Neurosyphilis
• Ocular or otic syphilis
• Syphilis during pregnancy with sonographic signs of 
fetal or placental syphilis
Complex vaginal discharge, trichomoniasis, and 
candidiasis
• Persistent vaginal discharge of unclear etiology
• Persistent or recurrent trichomoniasis
• IgE-mediated allergy to nitroimidazoles
• Recurrent vulvovaginal candidiasis in patients who 
remain culture-positive despite maintenance therapy
• Recurrent nonalbicans vulvovaginal candidiasis
Complex PID
• Cephalosporin or IgE-mediated penicillin allergy 
(quinolone resistant gonorrhea or antimicrobial 
susceptibility cannot be assessed)
• PID surgical complications (e.g., tubo-ovarian abscess)
Complex herpes
• Antiviral-resistant herpes infection
• Genital herpes contracted during third trimester of 
pregnancy
• Neonatal herpes
Viral hepatitis
• Hepatitis B infection
• Hepatitis C infection
Complex warts
• Cervical or intra-anal warts
• Atypical anogenital warts with high-grade squamous 
intraepithelial lesion on biopsy
Cervical intraepithelial neoplasia or cervical cancer
• Women with high- or low-grade squamous 
intraepithelial lesions on Pap smear
Complex ectoparasitic infections
• Crusted scabies in persons with HIV infection
Sexual assault
• HIV nPEP being considered
• STDs in children (if suspected possibility of 
sexual abuse)
HIV infection
• New diagnosis or establish link to care
Abbreviations: HIV = human immunodeficiency virus; IgE = immunoglobulin E; nPEP = nonoccupational postexposure prophylaxis; Pap = Papanicolaou; 
PID = pelvic inflammatory disease; PrEP = preexposure prophylaxis; STD = sexually transmitted disease.
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